Nirsevimab is a Monoclonal Antibody owned by AstraZeneca, and is involved in 7 clinical trials, of which 3 were completed, and 4 are ongoing.
Nirsevimab (MEDI-8897, SP-0232) is an RSV mAb. It acts by neutralizing the RSV-F protein. The antibody D25 binds to the RSV F protein prefusion complex. The cocrystal structure for one of these antibodies, D25, in complex with the F glycoprotein revealed D25 to lock F in its prefusion state by binding to a quaternary epitope at the trimer apex. They recognize a prefusion complex of the RSV-F protein. By targeting the RSV-F protein in the compact prefusion conformation, these antibodies could halt the critical unfolding of this protein into the conformation required for viral entry into cells.
The revenue for Nirsevimab is expected to reach a total of $12.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Nirsevimab NPV Report.
Nirsevimab (Beyfortus) is a human recombinant monoclonal antibody. It is formulated as a solution for the intramuscular route of administration. Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.
Nirsevimab (MEDI-8897, SP-0232) is under development for the prevention of lower respiratory tract disease caused by respiratory syncytial virus infection in infants. It is administered intramuscularly as a solution. It is a D25 RSV-specific antibody and it is engineered with a triple-amino-acid (M252Y/S254T/T256E [YTE]) substitution within its Fc region. These antibodies are specific for the RSV-F protein. It is based on AIMSelect And AIMProve technology.
Swedish Orphan Biovitrum Overview
Swedish Orphan Biovitrum (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS) and Hemophilia A. Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.
The company reported revenues of (Swedish Krona) SEK15,529 million for the fiscal year ended December 2021 (FY2021), an increase of 1.8% over FY2020. In FY2021, the company’s operating margin was 24%, compared to an operating margin of 31.6% in FY2020. In FY2021, the company recorded a net margin of 17.3%, compared to a net margin of 21.3% in FY2020. The company reported revenues of SEK3,999 million for the third quarter ended September 2022, an increase of 3.2% over the previous quarter.
Quick View – Nirsevimab
|Highest Development Stage|